FREMONT, Calif., Oct. 13 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. today announced the filing with the U.S. Securities and Exchange Commission of Prospectus Supplement No. 1 to the Prospectus contained in Post-Effective Amendment No. 2 to Form S-3 Registration Statement relating to the 2.00% Convertible Senior Notes due 2012 in an aggregate amount of $250.0 million. The offering of the notes was completed in February 2005 pursuant to Rule 144A under the Securities Act of 1933, as amended.
About PDL BioPharma
PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life- threatening illnesses. The company currently markets and sells a portfolio of leading products in the acute-care hospital setting in the United States and Canada and generates royalties through licensing agreements with top-tier biotechnology and pharmaceutical companies based on its pioneering antibody humanization technology. Currently, PDL's diverse product pipeline includes investigational compounds in Phase 2 or Phase 3 clinical development for inflammation and autoimmune diseases, cardiovascular disorders and cancer. The company's research platform is focused on the discovery and development of antibodies for the treatment of cancer and autoimmune diseases. For more information, please see PDL's website at www.pdl.com .
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.
PDL BioPharma, Inc.CONTACT: Ami Knoefler, Corporate and Investor Relations of PDL BioPharma,+1-510-284-8851, or ami.knoefler@pdl.com
Web site: http://www.pdl.com//
